Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
This oncologic clinical trial evaluates the efficacy and safety of the CDK 4/6 Inhibitor Abemaciclib in combination with endocrine therapy in high-risk early breast cancer patients
Cologne, Germany, 07.01.2021 – CANKADO, the leading digital health application developers in Germany, assists the recently started clinical trial, ADAPTlate, organized by West German Study Group (WSG) to collect the Patient Reported Outcomes (PROs) by the CANKADO ePRO tool. The clinical trial already enrolled the first patients who are using the CANKADO e-Health system as part of the study to monitor their Quality of Life (QoL). The trial aims to gain further knowledge on the efficacy and safety of the Abemaciclib treatment in combination with endocrine therapy versus standard endocrine therapy in HR+/HER2- early breast cancer patients with high risk for disease recurrence.
CANKADOs e-Health-System unterstützt die neue klinische Prüfung ADAPTlate pressnetwork.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressnetwork.de Daily Mail and Mail on Sunday newspapers.
Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now, we re going to talk about a really interesting set of presentations at San Antonio that I think really do have direct implications for clinical practice on Monday and this is the use of genomic tests and in some of the studies, Ki67 in order to try and inform us about how to treat our patients who have higher risk node-positive disease.
WSG and CANKADO's EnReP predicts the benefits of anti-hormone openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.